A Multicenter, Randomized, Open-Label Study of the Safety and Effectiveness of Pegylated Interferon Alpha 2b and Interferon Alpha 2b in Treating HBeAg Positive Chronic Hepatitis B Patients

Hong ZHAO,Chong-wen SI,Lai WEI,Mo-bin WAN,You-kuan YING,Jin-lin HOU,Jun-qi NUI

DOI: https://doi.org/10.3760/j.issn:1007-3418.2006.05.002

2006-01-01

Abstract:Objective To compare the efficacy and safety of PEG-IFN α -2b (Peg-Intron) with IFN α -2b (Intron A) in treating HBeAg positive chronic hepatitis B patients. Methods Two hundred thirty chronic hepatitis B (CHB) patients eligible to the following criteria were enrolled into this study: HBsAg and HBeAg(Abbott kit) positive for at least 6 months, serum HBV DNA ≥ 105 copies/ml (real time PCR, LLQ 103 copies/ml) and ALT ≥ 2 × ULN. After 1:1 randomization, the patients received Peglntron (group A: 1.0 μg/kg body weight, SC, once a week) or Intron A (group B: 3 MIU SC, three times a week) for 24 weeks, and followed up for 24 weeks. Results (1) In groups A and B, respectively, 80.87% and 83.48% were males; their median ages were 31.0 and 32.0 years old; their median body weights were 65.6 and 65.5 kg; mean serum HBV DNA loads were 8.06 logio and 7.99 logio; their mean ALT values were 4.17 × ULN and 3.77 × ULN. All of the above parameters between the two groups had no statistically significance differences. (2) At the end of treatment and after follow-up, compared to the Intron A group, the Peglntron group showed better response (including complete and partial response rate, HBV-DNA undetectable rate, HBeAg seroconversion rate), but the differences of all of them had no statistical significance. The rate of HBeAg loss was higher in patients receiving Peglntron after follow-up (P = 0.042 4). (Table 2) (3) Peglntron and Intron A reduced serum HBV DAN persistently during the therapy. Mean reduction at the end of the treatment was much higher in the Peglntron group than in the Intron group (2.22 logio copies/ml vs 1.66 logm copies/ml, P - 0.028 3). (4) The overall incidence of adverse events (AEs) in the PegIntron group was similar to that of the Intron A group (94.78% vs 95.65%). The AEs associated with Peglntron administration were similar in nature to those with Interon A, such as influenza-like symptoms, fever, fatigue, headache, nausea, etc and the differences of their incidences had no statistical significance. Conclusions The efficacy and safety of PEG-IFN α -2b treatment for CHB patients seems to be better than that of IFN α -2b; however, further studies are needed to confirm it.